RoboSense Wins CES 2020 Innovation Award for Autonomous Vehicle Technology
RoboSense http://www.robosense.ai, the world’s leading autonomous driving LiDAR perception solution provider, announced today that it has won the CES 2020 Innovation Award the second year in a row for autonomous vehicle technology. RoboSense won this year’s CES 2020 Innovation Award for the first MEMS-based Smart LiDAR Sensor, the RoboSense RS-LiDAR-M1, winning in the Vehicle Intelligence and Self-Driving Technology category.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191108005194/en/
RoboSense RS-LiDAR-M1 (Graphic: Business Wire)
The RoboSense award-winning RS-LiDAR-M1 is the world’s first and only MEMS-based smart LiDAR sensor for self-driving passenger vehicles with its own embedded AI algorithm technologies and SoC(System on a Chip). The RS-LiDAR-M1 goes beyond traditional LiDAR, providing full data collection and comprehension. As a ground-breaking product, the RS-LiDAR-M1 not only collects and interprets high definition 3D point cloud data, but also processes road data in real-time, with a built-in AI algorithm and SoC, while at the same time synchronizing high-precision positioning output; road traffic signage; lane markings, driving areas, road curbs, and obstacle detection; tracking; and classification. Also, it is the world’s smallest MEMS-based solid-state LiDAR, providing a low cost, high stability, and superior manufacturability to meet automotive-grade and serial production requirements.
“Driving Safety is the most critical challenge for the Autonomous driving vehicles. Perception is the first sense for the AD vehicles to precept the surrounding environment. To ensure a completely safe perception working in all conditions, LiDAR with smart perception algorithm and supporting functions are indispensable. We are very proud that our smart LiDR sensor concept have been recognized by the customers and different application users, ” said Dr. Leilei Shinohara, RoboSense Vice President of R&D.
The RoboSenseRS-LiDAR-M1 Smart LiDAR Sensor will be on display in the Innovation Awards Showcaseat the upcoming CES 2020. The complete list of CES 2020 Innovation Honorees, including product descriptions and photos, can be found at CES.tech/Innovation. RoboSense will be exhibiting at booth 6138, LVCC North Hall, CES 2020 from Jan. 7 – 10, 2020, and tabletop No. 602 at CES Unveiled Las Vegas, on Jan. 5, 2020, 5 – 8:30 p.m. PST.
About CES & CES Innovation Awards
An annual program that celebrates outstanding design, the CES Innovation Awards recognizes the best technology products of the year. The CES Innovation Awards are sponsored by the Consumer Technology Association (CTA)™, owner and producer of CES, the world’s largest and most influential technology event.
CES 2020 will showcase life-changing technology across every major industry. CES provides access to the very latest transformative tech, such as 5G connectivity, artificial intelligence, augmented and virtual reality, smart home, smart cities, sports tech, machine learning and more. For the latest news and show announcements, visit CES.tech. Follow CES online at CES.tech and on social.
About RoboSense
Founded in 2014, RoboSense is the world’s leading provider of LiDAR environment perception solutions designed to provide a higher performance, safer, more reliable, and lower cost LiDAR system for autonomous vehicles. RoboSense has entered into strategic partnerships with many top car companies, tier one manufacturers and technology companies with a global reach. For more information about RoboSense, visit: https://www.robosense.ai
Photos:
CES 2020 Innovation Award Honoree Logo: http://www.thomas-pr.com/136/photos/robosenseces2020innovationawardlogo.html
RS-LiDAR-M1 Smart LiDAR Sensor: http://www.thomas-pr.com/136/photos/robosensem1lidar.html
RoboSense Logo: http://www.thomas-pr.com/136/photos/robosenselogo.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191108005194/en/
Contact information
Press:
Karen Thomas/Eva Yutani
Emails: kthomas@thomaspr.com / eyutani@thomaspr.com
(631) 549-7575 website: http://www.thomaspr.com
Company:
Cassie Gong, Overseas PR Manager
Email: sqgong@robosense.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom